Topics

12/11/18

Kenneth E. Leonard, PhD, professor of psychiatry and director of the UB Clinical and Research Institute on Addictions (CRIA), and Peter L. Elkin, MD, professor and chair of biomedical informatics, have been awarded a two-year, $386,013 grant from the National Institute on Alcohol Abuse and Alcoholism to assess what risks may occur for people with alcohol use disorder (AUD) who use prescription painkillers.

12/11/18

Jennifer A. Martin, a doctoral student in the Department of Pharmacology and Toxicology, has received a prestigious Blueprint Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience Award from the National Institutes of Health (NIH).

12/3/18

An innovative, cost-effective program at more than a dozen hospitals in Western New York provides medication-assisted treatment to opioid use disorder patients in emergency departments (EDs) and rapidly transitions them into long-term treatment at a community clinic, all within about 48 hours.

11/20/18

Interprofessional collaboration is a key component in addressing the nation’s opioid epidemic, students from the Jacobs School of Medicine and Biomedical Sciences and other UB schools were told during the third annual forum on the topic.

5/24/18

UB’s Clinical and Translational Science Institute (CTSI) has awarded new grants that support promising translational research projects in Western New York.

4/18/18

Research led by senior author David Dietz, PhD, has revealed that in certain types of brain cells, drug-induced plasticity can work to reduce motivation for heroin.

3/22/18

A total of 37 original research projects from aspiring physician-scientists were on display at the 2018 Medical Student Research Forum.

1/10/18

The Western New York community has enlisted experts from the Jacobs School of Medicine and Biomedical Sciences to help combat the national opioid epidemic, which has reached crisis proportions.

12/11/17

The value of interprofessional collaboration in dealing with the opioid crisis was highlighted as students and staff from the Jacobs School of Medicine and Biomedical Sciences joined other UB schools of study during a forum on opioid dependence.

10/12/17

The Research Institute on Addictions (RIA) and faculty from the Jacobs School of Medicine and Biomedical Sciences (JSMBS) are leading an effort to combat the opioid crisis throughout the state.

5/3/17

UB researchers are developing innovative ways to better diagnose and treat hepatitis C virus (HCV) in people with substance abuse disorders.

1/31/17

Students from the Jacobs School of Medicine and Biomedical Sciences joined hundreds of their UB peers in the health professions, social work, law and management for an interprofessional forum on opioid dependence.

6/9/16

Andrew H. Talal, MD, professor of medicine in the Division of Gastroenterology, Hepatology and Nutrition, has received a $7 million grant to develop an effective way to treat drug users with the hepatitis C virus (HCV).

5/2/16

Jun-Xu Li, MD, PhD, assistant professor of pharmacology and toxicology, has received the Joseph Cochin Young Investigator Award from the College of Problems of Drug Dependence (CPDD) for his research on pharmacotherapy for stimulant abuse.

4/6/16

According to a fact sheet released by the White House, the Jacobs School of Medicine and Biomedical Sciences is among medical schools nationwide at the forefront of fighting the opioid epidemic.

8/27/15

Researchers in the lab of David Dietz, PhD, assistant professor of pharmacology and toxicology, discovered an unknown neural pathway that can regulate changes made in the brain from cocaine use. 

8/13/15

Torin J. Finver, MD, program director for the Department of Family Medicine’s addiction medicine fellowship, has been appointed to the board of directors for the New York Society of Addiction Medicine (NYSAM).

9/19/14

Research by David Dietz, PhD, has the potential to identify novel therapies to treat addiction to cocaine and other psychostimulants, for which no effective drug therapy exists.

7/11/14

Research co-authored by Andrew H. Talal, MD, shows that injection drug users who are enrolled in a treatment program want to be educated about hepatitis C virus (HCV) and are willing to be treated.

3/7/14

The risks of the new painkiller Zohydro — an extended-release formulation of hydrocodone — far outweigh the benefits and could lead to more overdoses, according to Richard D. Blondell, MD, vice chair for addiction medicine and professor of family medicine.